Verzenio (abemaciclib) NDC 0002-4483

NDC codes

FDA NDC Directory

Product NDC (as listed)0002-4483Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00002-4483Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0002-4483-54	00002448354	1 BLISTER PACK in 1 CARTON (0002-4483-54) / 14 TABLET in 1 BLISTER PACKMarketed from Oct 6, 2017
0002-4483-62	00002448362	2 BLISTER PACK in 1 CARTON (0002-4483-62) / 14 TABLET in 1 BLISTER PACKMarketed from Feb 15, 2025 · Sample package

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Verzenio
Generic name (nonproprietary): abemaciclib
Active ingredients: Abemaciclib — 50 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Eli Lilly and Company
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 208716
Marketing start: Sep 28, 2017
Listing expires: Dec 31, 2027
Other FDA classes: Kinase Inhibitors (Mechanism)
Identifiers: Product ID 0002-4483_5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0SPL ID 5b2d0f4e-5bba-4048-a2f0-bcb4b779efc0SPL set ID be4bc0de-0fdc-4d46-8d25-be43c79e6a06RxCUI 1946830, 1946836, 1946838, 1946840, 1946842, 1946844, 1946846, 1946848UNII 60UAB198HK
Pharmacologic class: Kinase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400002448354 followed by a unit qualifier and the quantity

Package 00002-4483-54. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 13, 2026.

Indications (excerpt from the label)

VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, hum…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 208716

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 208716
Product	Strength	Form · route	Labeler	Product NDC
Verzenioabemaciclib	Abemaciclib 200 mg/1	TabletOral	Eli Lilly and Company	0002-6216
Verzenioabemaciclib	Abemaciclib 100 mg/1	TabletOral	Eli Lilly and Company	0002-4815
Verzenioabemaciclib	Abemaciclib 150 mg/1	TabletOral	Eli Lilly and Company	0002-5337